The emergence of novel approaches, such as antibody-drug conjugates (ADCs), KRAS G12C inhibitors, and novel combinations such as tyrosine kinase inhibitor (TKI)/immune checkpoint inhibitors, exhibits promising outcomes in gastrointestinal (GI) cancers, according to Wells Messersmith, MD.